We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ALLMERCAP mercaptopurine monohydrate 20mg/mL oral liquid suspension bottle, Link Medical Products Pty Ltd T A Link Pharmaceuticals, CON-1283
Product name
ALLMERCAP mercaptopurine monohydrate 20mg/mL oral liquid suspension bottle
Sponsor name
Link Medical Products Pty Ltd T A Link Pharmaceuticals
Consent start
Consent no.
CON-1283
Duration
The consent is effective from 21 October 2024 until 31 August 2025.
Standard
Paragraphs 8(1)(a) and 9(1)(a); Paragraphs 8(1)(b) and 9(1)(b); Subparagraph 8(1)(j)(iv)(A); Paragraph 9(3)(a); Paragraph 8(1)(i); Paragraph 10(4)(j); Subsection 11(5) of Therapeutic Goods Order No. 91 - Standard for labels of prescription and related medicines
Non-compliance with standard
The products will be supplied in the UK approved packaging which has the
following differences: the name Xaluprine in place of Allmercap; the active
ingredient name is referred to as mercaptopurine instead of mercaptopurine
monohydrate; the name and quantity of the active ingredient are not in a
cohesive unit with the name of the medicine; the storage statement is not in the
permitted format; the Schedule 1 substances are not expressed as required; the
sponsors name and address are not included on the label and the name of the
sponsor is not included on the bottle label.
Conditions imposed
A ‘Dear Healthcare Provider’ letter will be supplied with each affected batch
describing the differences in the labels. Sponsor details will be attached to
the labels in such a way as to not impact any other relevant information on the
labels. Signal headings and the registration number will be attached.
Import, Supply, &/or Export
import and supply
Therapeutic product type
Prescription medicines